View­Point Ther­a­peu­tics gets $35M to ad­vance non-sur­gi­cal al­ter­na­tive for cataracts, pres­by­opia

With help from a so­cial­ly con­scious fund, San Fran­cis­co pro­tein mis­fold­ing up­start View­Point Ther­a­peu­tics has raised $35 mil­lion to take its eye drugs through proof-of-con­cept stud­ies.

The pro­ceeds from the Se­ries B fi­nanc­ing — led by The Rise Fund — will fu­el ear­ly stud­ies of VP1-001, View­Point’s lead prod­uct, in cataracts and pres­by­opia. Both eye dis­eases are age-re­lat­ed to dif­fer­ent de­grees, and cur­rent treat­ments all in­volve some form of surgery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER